CLK-peptide and SLK-peptide

Details CLK-peptide and SLK-peptide CLK-peptide and SLK-peptide

2004-02-18

2009-10-13

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S014800, C530S327000

Reexamination Certificate

active

07601694

ABSTRACT:
The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.

REFERENCES:
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5112946 (1992-05-01), Maione
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 6071520 (2000-06-01), Noteborn et al.
patent: 7122635 (2006-10-01), Brooks et al.
patent: 2004/0224896 (2004-11-01), Brooks et al.
patent: WO 00/40597 (2000-07-01), None
patent: WO-00/40597 (2000-07-01), None
patent: WO-00-59532 (2000-10-01), None
patent: WO-2004-73649 (2004-02-01), None
Amstutz, et al., In vitro display technologies: novel developments and applications. Current Opinion in Biotechnology 2001;12:400-405.
Engel J, Versatile collagens in invertebrates. Science 1997;277:1785-1786.
Gordon, et al., The contribution of collagenous proteins to tissue-specific matrix assemblies. Current Opinion in Cell Biology 1990;2:833-838.
Green, et al., Proc. Natl. Acad. Sci. USA 2003;100:1010-1015.
Guo, et al., In vitro evolution of amphioxus insulin-like peptide to mammalian insulin. Biochemistry 2002;41:10603-10607.
Hangai, et al., Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. American Journal of Pathology 2002;161(4):1429-1437.
Heeley RP, Endocr. Res. 2002;28:217-229.
Ingham, et al., Type I collagen contains at least 14 cryptic fibronectin binding sires of similar affinity. Archives of Biochemistry and Biophysics 2002;407:217-223.
Liljeblad, et al., Analysis of agalacto-IgG in rheumatoid arthritis using surface plasmon resonance. Glycoconjugate Journal 2000;17:323-329.
Stephanopoulos G, Metabolic engineering by genome shuffling. Nature Biotechnology 2002;20(7):666-668.
Tani, et al., In vitro selection o fibronectin gain-of-function mutations. Biochem. J. 2002;365:287-294.
Steffensen, et al., Human fibronectin and MMp-2 collagen binding domains compete for collagen binding sites and modify cellular activation of MMP-2. Matrix Biology 2002;21:399-414.
Varner, et al., Cell Adh. Commun. 1995;3:367-374.
Xu, et al., Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 2000;19(5)375-385.
Xu, et al., Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. Journal of Cell Biology 2001;154(5):1069-1079.
Zhao, et al., Directed evolution of enzymes and pathways for industrial biocatalysis. Current Opinion in Biotechnology 2002;13:104-110.
Akalu, A. et al., “Inhibition of Angiogenesis and Tumor Metastasis by Targeting a Matrix Immobilized Cryptic Extracellular Matrix Epitope in Laminin,” Cancer Res. 67(9):4353-4363 (2007).
Auerbach, R. et al., “Angiogenesis Assays: A Critical Overview,” Clin. Chem. 49(1):32-40 (2003).
Auerbach, R. et al., “Angiogenesis assays: Problems and pitfalls,” Cancer Metastasis Rev. 19:167-172 (2000).
Battegay, E.J., “Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects,” J. Mol. Med. 73:333-346 (1995).
Blood, C.H. et al., “Tumor interactions with the vasculature: angiogenesis and tumor metastasis,” Biochim. Biophys. Acta. 1032:89-118 (1990).
Brooks, P. et al., “Integrin αvβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels,” Cell 79:1157-1162 (1994).
Brooks, P. et al., “Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity,” Cell 92:391-400 (1998).
Brooks, P. et al., “Antiintegrin αvβ3blocks human breast cancer growth and angiogenesis in human skin,” J. Clin. Invest. 96:1815-1822 (1995).
Burgess, W.H. et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” J. Cell. Biol. 111:2129-2138 (1990).
Fischer, C., “Principles and Therapeutic Implications of Angiogenesis, Vasculogenesis and Arteriogenesis,” HEP 176(11):157-212 (2006).
Gonzalez, A. et al., “Complex interactions between the laminin alpha 4 subunit and integrins egulate endothelial cell behavior in vitro and angiogenesis in vivo,” PNAS USA 99(25):16075-16080 (2002).
Guo, H. et al., “Protein tolerance to random amino acid change,” PNAS USA 101(25):9205-9210 (2004).
Jo, N. et al., “Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization,” Mol. Vision 12:1243-1249 (2006).
Jones, D.T., “Critically assessing the state-of-the-art in protein structure prediction,” Pharmacogenomics J. 1:126-134 (2001).
Kim, J. et al., “Inhibition of Angiogenesis and Angiogenesis-dependent Tumor Growth by the Cryptic Kringle Fragments of Human Apolipoprotein(a),” J. Biol. Chem. 278:29000-29008 (2003).
Kim, S. et al., “Regulation of Angiogenesis In Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin,” Am. J. Path. 156:1345-1362 (2000).
Kikkawa, Y. et al., “Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells. Laminin-10/11 mediates cell adhesion through integrin alpha3 beta1,” J. Biol. Chem. (online), Am. Soc. Biochem. Mol. Biol., 273 (25):15854-15859 (1998).
Kurkinen, M. et al., “In vitro synthesis of laminin and entactin polypeptides,” J. Biol. Chem. 258(10):6543-6548 (1983).
Kurschat, P., “Mechanisms of Metastasis,” Clin. Exp. Dermatol. 25:482-489 (2000).
Lazar, E. et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Mol. Cell. Biol. 8:1247-1252 (1998).
Liotta, L. A. et al., “Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation,” Cell 65:327-336 (1991).
National Cancer Institute, “Radiation Therapy”, www.cancer.gov.
Qin, X. et al., “Structure-Function Analysis of the Human Insulin-like Growth Factor Binding Protein-4,” JBC 273(36):23509-23516 (1998).
Roskelley, C.D. et al., “A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression,” Curr. Op. Cell Biol. 7:736-747 (1995).
Skolnick, J. et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends Biotech. 18:34-39 (2000).
Staton, C.A. et al., “Current methods for assaying angiogenesis in vitro and in vivo,” Intl J. Exp. Path. 85:233-248 (2004).
Tosatto, S.C.E. et al., “Large-Scale Prediction of Protein Structure and Function from Sequence,” Curr. Pharma. Des. 12:2067-2086 (2006).
Weidner, N. et al., “Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma,” J. Natl. Cancer Inst. 84:1875-1887 (1992).
Weidner, N. et al., “Tumor Angiogensis and Metastasis-Correlation in Invasive Breast Carcinoma,” N. Engl. J. Med. 324:1-7 (1991).
Wyckoff, J., “A Critical Step in Metastasis: In Vivo Analysis of Intravasation at the Primary Tumor,” Cancer Res. 60:2504-2511 (2000).

Affiliated with

Also associated with

Rating

CLK-peptide and SLK-peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CLK-peptide and SLK-peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CLK-peptide and SLK-peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4063506